Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake
CompanyDeals

Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake

SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry
Policy / Regulatory

SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry

JD Healthcare and Genrix Bio Join Forces to Revolutionize Patient Care and Pharmacy Services
CompanyDeals

JD Healthcare and Genrix Bio Join Forces to Revolutionize Patient Care and Pharmacy Services

Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027
Policy / Regulatory

Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027

Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001
CompanyDrug

Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001

Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development
CompanyDeals

Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development

Pfizer's Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B
CompanyDrug

Pfizer’s Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B

Hetero and Gilead Sciences Partner to Expand Access to HIV Treatment in Low-Income Countries
CompanyDeals

Hetero and Gilead Sciences Partner to Expand Access to HIV Treatment in Low-Income Countries

Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market
CompanyDrug

Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market

Coherent Biopharma's CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer
CompanyDrug

Coherent Biopharma’s CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer

Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors
CompanyDrug

Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors

Harbour BioMed's Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma
CompanyDrug

Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma